<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05615545</url>
  </required_header>
  <id_info>
    <org_study_id>ZZUSC-10</org_study_id>
    <nct_id>NCT05615545</nct_id>
  </id_info>
  <brief_title>Cryoablation for Advanced Bone and Soft Tissue Tumors</brief_title>
  <official_title>Safety and Efficacy of Cryoablation in the Treatment of Advanced Bone and Soft Tissue Tumors: a Single-center Retrospective Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Henan Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Henan Cancer Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single-center, open, retrospective clinical study of patients with&#xD;
      metastatic/surgically unresectable bone and soft tissue sarcoma undergoing cryoablation of&#xD;
      selected tumor lesions. All eligible patients were enrolled. Basic data and treatment methods&#xD;
      of these patients were collected, and efficacy and safety were evaluated.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a single-center, open, retrospective clinical study of patients with&#xD;
      metastatic/surgically unresectable bone and soft tissue sarcoma undergoing cryoablation of&#xD;
      selected tumor lesions. Clinical data of eligible patients were scheduled to be&#xD;
      retrospectively collected from December 2016 to February 28, 2022. All patients eligible for&#xD;
      inclusion. Basic data and treatment methods of these patients were collected, and efficacy&#xD;
      and safety were evaluated.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 10, 2022</start_date>
  <completion_date type="Anticipated">October 28, 2023</completion_date>
  <primary_completion_date type="Anticipated">October 28, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Survival rates</measure>
    <time_frame>12 months after surgery</time_frame>
    <description>1-year survival rate</description>
  </primary_outcome>
  <primary_outcome>
    <measure>There was no local recurrence survival rate</measure>
    <time_frame>12 months after surgery</time_frame>
    <description>The 1-year survival rate without local recurrence</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Sarcoma</condition>
  <condition>Cryoablation</condition>
  <arm_group>
    <arm_group_label>Cryoablation</arm_group_label>
    <description>Cryoablation of selected tumor lesions</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Cryoablation</intervention_name>
    <description>Cryoablation of selected tumor lesions</description>
    <arm_group_label>Cryoablation</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Cryoablation of selected tumor lesions in patients with metastatic/operatively unresectable&#xD;
        bone and soft tissue sarcomas&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        No age restriction, male or female.&#xD;
&#xD;
        The pathological diagnosis was a subtype of bone and soft tissue sarcoma.&#xD;
&#xD;
        The clinical stage was determined to be metastatic or locally unresectable bone and soft&#xD;
        tissue sarcoma.&#xD;
&#xD;
        At least one cryoablation of tumor lesions was performed in our hospital.&#xD;
&#xD;
        Target lesions can be evaluated according to the efficacy evaluation criteria for solid&#xD;
        tumors (RECIST; Version 1.1) Measure diameter changes.&#xD;
&#xD;
        Follow-up data were complete.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Not applicable.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Wang Jiaqiang, Dr</last_name>
    <phone>13592413731</phone>
    <email>wjqwtj@126.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tian Zhichao, Dr</last_name>
    <phone>18737187831</phone>
    <email>tianzhichaoyy@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Bone and Soft Tissue ,Henan Cancer Hospital</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <zip>450008</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tian Zhichao, Dr.</last_name>
      <phone>+8618737187831</phone>
      <email>tianzhichhaoyy@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2022</verification_date>
  <study_first_submitted>November 7, 2022</study_first_submitted>
  <study_first_submitted_qc>November 7, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 14, 2022</study_first_posted>
  <last_update_submitted>March 31, 2023</last_update_submitted>
  <last_update_submitted_qc>March 31, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">April 3, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Henan Cancer Hospital</investigator_affiliation>
    <investigator_full_name>Wang Jiaqiang</investigator_full_name>
    <investigator_title>associate chief physician</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Soft Tissue Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

